Niagen Bioscience Study Links NR Supplementation to Reduced Muscle Epigenetic Aging — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience published a peer-reviewed analysis showing Niagen® (NR) supplementation reduced muscle epigenetic age acceleration by ~2.5 years over five months.
The study, led by researchers from Finland and Australia, analyzed data from three prior clinical trials using seven epigenetic clocks.
Mitochondrial content changes correlated with epigenetic age acceleration, suggesting a link between NAD+ restoration and biological aging markers.
Six of seven skeletal muscle epigenetic clocks showed reductions in age acceleration post-supplementation, though one clock (PCGrimAge) indicated increased aging.

The big picture

This analysis strengthens Niagen Bioscience’s scientific case for NAD+ restoration as a tool for modulating biological aging, particularly in skeletal muscle. The findings come amid growing interest in epigenetic clocks as biomarkers for interventions targeting healthspan extension. With Tru Niagen® as the leading NAD+-boosting supplement in the U.S., the company is well-positioned to capitalize on this research if replicated.

What we're watching

Clinical Validation: Whether follow-up studies will confirm these findings in controlled trials designed specifically to test epigenetic aging outcomes.
Competitive Positioning: How Niagen Bioscience leverages this data to differentiate its NR products from exercise interventions and other NAD+-boosting supplements.
Regulatory Pathways: The pace at which the company advances its pharmaceutical-grade NAD+ therapies, given the study's implications for muscle aging treatments.